Clinical Trials Browser

Phase 3 × INDUSTRY × Filgrastim × Clear all

NCT06212752 2025-11-12

MK-3475A-D77

Phase 3 Active not recruiting

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT05722015 2025-09-11

MK-3475A-D77

Phase 3 Active not recruiting

377 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03504410 2023-02-08

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Phase 3 Terminated

200 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02104830 2016-10-24

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Phase 3 Completed

135 enrolled 18 charts

BreastClassical hematology

Breast Neoplasms, Neutropenia, Febrile Neutropenia

NCT01519700 2015-05-06

PIONEER

Phase 3 Completed

218 enrolled 15 charts

Breast Neoplasms, Neutropenia

NCT01767714 2014-12-09

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Phase 3 Completed

Lymphoma, Non-Hodgkin